These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21187514)

  • 1. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
    Farkouh A; Ettlinger D; Schueller J; Georgopoulos A; Scheithauer W; Czejka M
    Anticancer Res; 2010 Dec; 30(12):5207-11. PubMed ID: 21187514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
    Schreiber V; Kitzmueller M; Poxhofer M; Gintersdorfer S; Neudorfer C; Lichtneckert M; Dittrich C; Czejka M
    Anticancer Res; 2014 Jul; 34(7):3371-6. PubMed ID: 24982342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
    Dennie TW; Fleming RA; Bowen CJ; Dar MM; Alberti D; Oliver K; Loconte N; Mulkerin D; Holen KD
    Clin Colorectal Cancer; 2011 Mar; 10(1):57-62. PubMed ID: 21609937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
    Iqbal S; Lenz HJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
    Farid M; Chowbay B; Chen X; Tan SH; Ramasamy S; Koo WH; Toh HC; Choo SP; Ong SY
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):141-50. PubMed ID: 22648745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
    Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and simplified HPLC-UV method with on-line wavelengths switching for determination of capecitabine in human plasma.
    Piórkowska E; Kaza M; Fitatiuk J; Szlaska I; Pawiński T; Rudzki PJ
    Pharmazie; 2014 Jul; 69(7):500-5. PubMed ID: 25073394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of toxicity caused by drug interaction between capecitabine and phenytoin in patient with colorectal cancer].
    Sakurai M; Kawahara K; Ueda R; Fukui E; Yamada R
    Gan To Kagaku Ryoho; 2011 May; 38(5):841-3. PubMed ID: 21566450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.
    Xu Y; Grem JL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):273-85. PubMed ID: 12450548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
    Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
    Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
    Chu E; Schulman KL; McKenna EF; Cartwright T
    Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
    Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
    Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
    Farkouh A; Schueller J; Scheithauer W; Czejka M
    Int J Clin Pharmacol Ther; 2010 Jul; 48(7):487-8. PubMed ID: 20557855
    [No Abstract]   [Full Text] [Related]  

  • 15. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
    Carrato A; Gallego-Plazas J; Guillén-Ponce C
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection.
    Zufía L; Aldaz A; Giráldez J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 809(1):51-8. PubMed ID: 15282093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
    Deenen MJ; Rosing H; Hillebrand MJ; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():30-40. PubMed ID: 23270936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
    Farkouh A; Scheithauer W; Buchner P; Georgopoulos A; Schueller J; Gruenberger B; Czejka M
    Anticancer Res; 2014 Jul; 34(7):3669-73. PubMed ID: 24982385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.